MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc has a research collaboration and evaluation agreement with Janssen Pharmaceuticals, Inc. the company was founded in 2015 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTX
Previous Symbol
CUSIPN/A
Phone646-490-2965
Debt
Debt-to-Equity RatioN/A
Current Ratio10.77
Quick Ratio10.77
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-31,040,000.00
Net MarginsN/A
Return on Equity-291.76%
Return on Assets-94.04%
Miscellaneous
Employees59
Outstanding Shares27,390,000
Market Cap$331.10 million
OptionableNot Optionable
MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions
What is MeiraGTx's stock symbol?
MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."
How were MeiraGTx's earnings last quarter?
MeiraGTx Holdings PLC (NASDAQ:MGTX) announced its earnings results on Thursday, November, 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.01. View MeiraGTx's Earnings History.
When is MeiraGTx's next earnings date?
What price target have analysts set for MGTX?
4 Wall Street analysts have issued 1 year price targets for MeiraGTx's shares. Their predictions range from $20.00 to $30.00. On average, they expect MeiraGTx's stock price to reach $23.6667 in the next twelve months. This suggests a possible upside of 116.1% from the stock's current price. View Analyst Price Targets for MeiraGTx.
What is the consensus analysts' recommendation for MeiraGTx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.
What are Wall Street analysts saying about MeiraGTx stock?
Here are some recent quotes from research analysts about MeiraGTx stock:
- 1. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (12/18/2018)
- 2. Chardan Capital analysts commented, "We briefly discussed Meira’s riboswitch technology as part of our long-term overall platform thesis on Meira, in our initiation research referenced below: Our relevant MeiraGTx research: 23 August 2018: MGTX: a ‘RIX reward’ story and robust overall platform" Please refer to important disclosure information and Regulation Analyst Certification found on pages 4 – 9 of this report.Valuation: Our MGTX price target of $30 is based on a probability-adjusted modeling of key franchises. We use a DCF with a WACC of 12.6% and perpetuity growth of 1.0% (5.8x implied terminal EBITDA multiple) to derive our price target." (10/16/2018)
Has MeiraGTx been receiving favorable news coverage?
Press coverage about MGTX stock has been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MeiraGTx earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the near future.
Who are some of MeiraGTx's key competitors?
Some companies that are related to MeiraGTx include Autolus Therapeutics (AUTL), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), DBV TECHNOLOGIE/S (DBVT), Solid Biosciences (SLDB), Cellectis (CLLS), Acorda Therapeutics (ACOR), Vericel (VCEL) and Heska (HSKA).
Who are MeiraGTx's key executives?
MeiraGTx's management team includes the folowing people:
- Dr. Alexandria Forbes, CEO, Pres & Director (Age 53)
- Mr. Richard Brian Giroux, Chief Operating Officer (Age 45)
- Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 55)
- Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial Officer
- Prof. Gregory A. Petsko, Chief Scientist & Chairman of Scientific Advisory Board
When did MeiraGTx IPO?
(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.
When did the company's lock-up period expire?
MeiraGTx's lock-up period expired on Wednesday, December 5th. MeiraGTx had issued 5,000,000 shares in its IPO on June 8th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.
Who are MeiraGTx's major shareholders?
Which institutional investors are buying MeiraGTx stock?
How do I buy shares of MeiraGTx?
Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MeiraGTx's stock price today?
One share of MGTX stock can currently be purchased for approximately $10.95.
How big of a company is MeiraGTx?
MeiraGTx has a market capitalization of $331.10 million. MeiraGTx employs 59 workers across the globe.
What is MeiraGTx's official website?
How can I contact MeiraGTx?
MeiraGTx's mailing address is 430 EAST 29TH STREET 10TH FLOOR, NEW YORK NY, 10016. The company can be reached via phone at 646-490-2965 or via email at [email protected]
MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
